1. 96 Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo. (10th December 2020) Authors: Pankov, Dmitry; Eleftheriadou, Ioanna; Domogala, Anna; Brett, Sara; Patasic, Lea; Kijewska, Magdalena; Thripp, Gary; Euesden, Jack; Klapwijk, Jan; Soor, Katrina; Damm, Miriam; Hill, Mark D; Georgouli, Mirella; Shalabi, Aiman; Britten, Cedrik Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 96 Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo. (9th November 2020) Authors: Pankov, Dmitry; Eleftheriadou, Ioanna; Domogala, Anna; Brett, Sara; Patasic, Lea; Kijewska, Magdalena; Thripp, Gary; Euesden, Jack; Klapwijk, Jan; Soor, Katrina; Damm, Miriam; Hill, Mark D; Georgouli, Mirella; Shalabi, Aiman; Britten, Cedrik Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase 2 randomized, double-blind, placebo-controlled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma. (7th November 2013) Authors: Krug, Lee; di Pietro, Alessandra; Narwal, Rajesh; Robbins, Paul; Fu, Dongyue; Shalabi, Aiman; Ibrahim, Ramy; Calabro, Luana; Kindler, Hedy Journal: Journal for immunotherapy of cancer Issue: Volume 1(2013)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗